Research Article| Volume 36, ISSUE 1, P43-47, April 1989

The effect of an orally active leukotriene (LT) antagonist YM-16638 on antigen-induced early and late airway responses in allergic sheep

      This paper is only available as a PDF. To read, Please Download here.


      In this study we examined the effects of an orally active leukotriene (LT) antagonist YM-16638 [[5-[[3-(4-acetyl-3-hydroxy- 2-propyl-phenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio] acetic acid on antigen-induced early and late responses in allergic sheep. For all studies YM-16638 was administered via intragastric tube 1 h before airway challenge with Ascaris suum antigen. Six allergic sheep were challenged on four occassions (2 control and 2 drug trials) earch ≥14 days apart and the tests were conducted in the following order: control-1; YM-16638 30 mg/kg; control-2; YM-16638 10 mg/kg. Specific lung resistance (SRL) was used as an index of the airway response to antigen and was measured before and serially after antigen challenge. In both control trials antigen challenge resulted in significant early and late airway responses (i.e. increases in SRL); however, there was a significant difference between the peak late increases of SRL in control-1 (206%) and control-2 (115%) suggesting a carry-over effect of the 30 mg/kg dose of YM-16638. At both doses, YM-16638 reduced the early response and blocked the late response when compared to either control trial. These results suggest that sulfidopeptide LTs contribute to both antigen-induced early and late airway responses in allergic sheep.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abraham WM
        • Delehunt JC
        • Yerger L
        • Marchette B
        Characterization of a late phase pulmonary response followingantigen challenge in allergic sheep.
        Am. Rev. Respir. Dis. 1983; 128: 839
        • Lanes S
        • Stevenson JS
        • Codias E
        • Hernandez A
        • Sielczak MW
        • Wanner A
        • Abraham WM
        Indomethacin and FPL-27231 inhibit antigen-induced airway hyperresponsiveness in sheep.
        J. Appl. Physiol. 1986; 61: 864
        • Abraham WM
        • Wanner A
        • Stevenson JS
        • Chapman GA
        The effect of an orally active leukotriene Math Eq antagonist, LY171883, on antigen-induced airway responses in allergic sheep.
        Prostaglandins. 1986; 31: 457
        • Abraham WM
        • Stevenson JS
        • Garrido R
        The effect of an orally active leukotriene (LT) D4 antagonist WY-48,252 on LTD4 and antigen-induced bronchoconstrictions in allergic sheep.
        Prostaglandins. 1988; (In Press)
        • Fleisch JH
        • Rinkema LE
        • Haisch KD
        • Swarson-Bean D
        • Goodson T
        • Ho PPK
        • Marshall WS
        LY171883, 1-<2-Hydroxy-3-Propyl-4-<4-(1H-Tetrazol-5-yl) Butoxy>Phenyl>Ethanone, an orally active leukotriene D4 antagonist.
        J. Pharmacol. Exp. Ther. 1985; 233: 148
        • Hand JM
        • Musser JH
        • Kreft AF
        • Schwalm S
        • Englebach I
        • Auen M
        • Skowronek M
        • Chang JY
        Wy-48,252 (1,1,1-trifluoro-N-[3-(2-quinolinylmethoxy)phenyl]methane sulfonamide) an orally active leukotriene antagonist: Pharmacological characterization in vitro and in vivo in the guinea pig.
        The Pharmacologist. 1987; 29: 174
        • Weichman BM
        • Wasserman MA
        • Gleason JG
        SK&F 88046: a unique pharmacologic antagonist of broncho-constriction induced by leukotriene D4, thromboxane and prostaglandins F2 and D2 in vitro.
        J. Pharmacol. Exp. Ther. 1984; 228: 128
        • Allegra L
        • Abraham WM
        • Chapman GA
        • Wanner A
        Duration of mucociliary dysfunction following antigen challenge.
        J. Appl. Physiol. 1983; 55: 726
        • Tomioka K
        • Yamada T
        • Mase T
        • Hara H
        • Murase K
        Pharmacological properties of YM-16638, an orally active leukotriene antagonist.
        1988 (Submitted)
        • Tomioka K
        • Jackowski JT
        • Abraham WM
        Characterization of sulfidopeptide leukotriene responses in sheep tracheal smooth muscle in vitro.
        Am. Rev. Respir. Dis. 1988; 137: 100
        • Abraham WM
        The importance of lipoxygenase products of arachidonic acid in allergen-induced late responses.
        Am. Rev. Respir. Dis. 1987; 135: S49
        • Bernstein IL
        • Seigel SC
        • Brandon ML
        • Brown EB
        • Evans RR
        • Feinberg AR
        • Friedlaender S
        • Krumholz RA
        • Hadley RA
        • Handelman NI
        • Thurston D
        • Yamate M
        A controlled study of crcmolyn sodium sponsored by the drug committe of the American Academic of Allergy.
        J. Allergy Clin. Immunol. 1972; 50: 235